The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
NCT Number: NCT05060510
This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public health that provides take-home saliva testing kits in schools. Operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. The study will leverage this chance implementation to do a robust evaluation of the public health intervention. Schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. The investigators will evaluate the impact of the program on SARS-CoV-2 case identification in schools.
Looking for future studies?
Notify Me2 year and older
All sexes
Interventional
Not applicable
Toronto, Ontario, M5G 1X8, Canada
This is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design.
Eligible secondary public schools in Toronto Region will be randomized. The study will occur over a 7-week period with a minimum of one-week of baseline data (control phase - testing at an assessment center, primary care or acute care center) and then schools will start the program in a stepwise manner (10 crossovers per week) with take-home saliva being available to all 60 schools by the end of the study period. The primary objective of the study is to assess whether the availability of take home saliva kits at schools for symptomatic PCR testing leads to increased diagnosis of COVID-19 cases in the school.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Secondary schools will be included in the evaluation if they are:
Exclusion criteria
Schools that are middle schools only, that are not open for in-person learning, have fewer than 100 students or are not a complete secondary school (i.e. adult learning schools, schools offering independent courses, prep schools with 1-2 grades, secondary schools with < 4 grades) will be excluded.
Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
Time frame: Weekly measurement over 7 week study period
The number of cases positive for SARS-CoV-2 in a cohort per week per school (rate per cohort per week) in the intervention period compared to the control period.
Time frame: Weekly measurement over 7 week study period
Frequency of use of take-home saliva kits per school per week
Time frame: Over 7 week study period
To assess whether availability of take-home saliva kits at school leads to earlier testing as measured by duration of symptoms before testing of the symptomatic case
Time frame: Over 7 week study period
To assess whether the availability of take-home saliva testing leads to reduced transmission within exposed cohorts as measured by the number of secondary cases identified in exposed cohorts.
The Hospital for Sick Children
Other
The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program for COVID-19 Implemented With a Stepped-wedge Cluster Randomized Design in Secondary Schools.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05125887
COVID-19, Coronaviridae Infections
Limoges, France
View Trial DetailsNCT04590222
COVID-19, Coronaviridae Infections
Le Kremlin-Bicêtre, France
View Trial DetailsNCT06181292
COVID-19, Coronaviridae Infections
Badalona, Barcelona, Spain
View Trial DetailsNCT04470648
COVID-19, Coronaviridae Infections
Paris, France
View Trial Details